Clinical Trials Logo

HIV clinical trials

View clinical trials related to HIV.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03847376 Approved for marketing - HIV Clinical Trials

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

Start date: n/a
Phase:
Study type: Expanded Access

The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.